Intellia Therapeutics Inc
Closed
SectorHealthcare
11.73 -1.59
Overview
Share price change
24h
Min
11.71
Max
11.82
Income | -107M -203M |
|---|---|
Sales | -7.4M 7.7M |
EPS | -0.8 |
Profit margin | -2,648.714 |
Employees | 377 |
EBITDA | -11M -105M |
Next Earnings | 4 Nov 2026 |
|---|
Market Cap | 280M 1.8B |
|---|---|
Previous open | 13.32 |
Previous close | 11.73 |
News Sentiment
By Acuity
18%
82%
22 / 339 Healthcare
Intellia Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Intellia Therapeutics Inc Forecast
Sentiment
By Acuity
22 / 339 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.